PT2928878T - Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina contendo um grupo sulfoximina - Google Patents

Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina contendo um grupo sulfoximina

Info

Publication number
PT2928878T
PT2928878T PT137928859T PT13792885T PT2928878T PT 2928878 T PT2928878 T PT 2928878T PT 137928859 T PT137928859 T PT 137928859T PT 13792885 T PT13792885 T PT 13792885T PT 2928878 T PT2928878 T PT 2928878T
Authority
PT
Portugal
Prior art keywords
pyridin
fluoro
amine derivatives
derivatives containing
sulfoximine group
Prior art date
Application number
PT137928859T
Other languages
English (en)
Portuguese (pt)
Inventor
Lücking Ulrich
Bohlmann Rolf
Scholz Arne
Siemeister Gerhard
Bömer Ulf
Kosemund Dirk
Lienau Philip
Böhnke Niels
Zorn Ludwig
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PT2928878T publication Critical patent/PT2928878T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT137928859T 2012-11-15 2013-11-12 Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina contendo um grupo sulfoximina PT2928878T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12192852 2012-11-15

Publications (1)

Publication Number Publication Date
PT2928878T true PT2928878T (pt) 2017-02-08

Family

ID=47148672

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137928859T PT2928878T (pt) 2012-11-15 2013-11-12 Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina contendo um grupo sulfoximina

Country Status (42)

Country Link
US (2) US9650340B2 (enExample)
EP (1) EP2928878B1 (enExample)
JP (1) JP6263193B2 (enExample)
KR (1) KR102242871B1 (enExample)
CN (1) CN105102444B (enExample)
AP (1) AP3872A (enExample)
AR (1) AR093505A1 (enExample)
AU (1) AU2013346939B2 (enExample)
BR (1) BR112015010707B1 (enExample)
CA (1) CA2891358C (enExample)
CL (1) CL2015001304A1 (enExample)
CR (1) CR20150256A (enExample)
CU (1) CU20150052A7 (enExample)
CY (1) CY1118441T1 (enExample)
DK (1) DK2928878T3 (enExample)
DO (1) DOP2015000118A (enExample)
EA (1) EA027226B1 (enExample)
EC (1) ECSP15019323A (enExample)
ES (1) ES2612978T3 (enExample)
HR (1) HRP20161547T1 (enExample)
HU (1) HUE032868T2 (enExample)
IL (1) IL238322A (enExample)
JO (1) JO3332B1 (enExample)
LT (1) LT2928878T (enExample)
MA (1) MA38090B1 (enExample)
ME (1) ME02880B (enExample)
MX (1) MX374333B (enExample)
MY (1) MY170609A (enExample)
NZ (1) NZ707084A (enExample)
PE (1) PE20151071A1 (enExample)
PH (1) PH12015501003B1 (enExample)
PL (1) PL2928878T3 (enExample)
PT (1) PT2928878T (enExample)
RS (1) RS55580B1 (enExample)
SG (1) SG11201503079PA (enExample)
SI (1) SI2928878T1 (enExample)
SV (1) SV2015004979A (enExample)
TN (1) TN2015000185A1 (enExample)
TW (1) TWI613193B (enExample)
UA (1) UA115254C2 (enExample)
UY (1) UY35141A (enExample)
WO (1) WO2014076091A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
ES2595222T3 (es) 2012-10-18 2016-12-28 Bayer Pharma Aktiengesellschaft Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfona
CN105283453B (zh) 2012-10-18 2018-06-22 拜耳药业股份公司 含砜基的n-(吡啶-2-基)嘧啶-4-胺衍生物
US9650340B2 (en) 2012-11-15 2017-05-16 Bayer Pharma Aktiengesellschaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
PE20151054A1 (es) 2012-12-17 2015-08-07 Parion Sciences Inc Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
US9770445B2 (en) 2013-07-04 2017-09-26 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
CA2942119A1 (en) 2014-03-13 2015-09-17 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
EP3126338B1 (en) 2014-04-01 2019-09-04 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
CR20160471A (es) 2014-04-11 2016-12-21 Bayer Pharma AG Compuestos novedosos macrocíclicos
CN107207475A (zh) 2014-10-16 2017-09-26 拜耳医药股份有限公司 含有砜基团的氟化苯并呋喃基‑嘧啶衍生物
EP3207038B1 (en) 2014-10-16 2018-08-22 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
JP6847099B2 (ja) 2015-09-29 2021-03-24 バイエル ファーマ アクチエンゲゼルシャフト 新規な大環状スルホンジイミン化合物
CN108368129B (zh) 2015-10-08 2021-08-17 拜耳医药股份有限公司 改性大环化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3601253B1 (en) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
KR102764122B1 (ko) * 2018-02-13 2025-02-05 바이엘 악티엔게젤샤프트 미만성 거대 b-세포 림프종을 치료하기 위한 5-플루오로-4-(4-플루오로-2-메톡시페닐)-n-[4-[(s-메틸술폰이미도일)메틸]피리딘-2-일]피리딘-2-아민의 용도
JP2023505850A (ja) 2019-12-09 2023-02-13 石薬集団中奇制薬技術(石家庄)有限公司 サイクリン依存性キナーゼ9阻害剤としての化合物及びその用途
US20230106032A1 (en) * 2020-03-06 2023-04-06 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
WO2022078309A1 (zh) * 2020-10-12 2022-04-21 上海海雁医药科技有限公司 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途
CN117015539A (zh) * 2022-03-25 2023-11-07 成都苑东生物制药股份有限公司 一种氨基吡啶类衍生物、其制备方法及用途
WO2024044757A1 (en) * 2022-08-26 2024-02-29 Sanford Burnham Prebys Medical Discovery Institute Aminopyrimidine and aminotriazine derivatives as myc protein modulators
AU2023374476A1 (en) * 2022-11-02 2025-06-19 Lead Discovery Center Gmbh Combination therapies comprising a cdk9 inhibitor for cancer
WO2024112656A1 (en) * 2022-11-21 2024-05-30 The Board Of Trustees Of The Leland Stanford Junior University Use of a tyrosine kinase inhibitor for the treatment of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2556946T3 (es) 2000-12-21 2016-01-21 Novartis Ag Pirimidinaminas como moduladores de la angiogénesis
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20090099160A1 (en) 2004-12-17 2009-04-16 David Andrews 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
DE102006041382A1 (de) * 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
WO2008079933A2 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
WO2008079918A1 (en) 2006-12-22 2008-07-03 Novartis Ag Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
JP5566880B2 (ja) * 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体
JP5693951B2 (ja) 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
JP5921525B2 (ja) 2010-03-22 2016-05-24 リード ディスカバリー センター ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬的に活性のある二置換のトリアジン誘導体
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
ES2567066T3 (es) * 2011-03-02 2016-04-19 Lead Discovery Center Gmbh Derivados de piridina disustituida farmacéuticamente activos
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
WO2013037894A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
CA2848616A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
ES2595222T3 (es) * 2012-10-18 2016-12-28 Bayer Pharma Aktiengesellschaft Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfona
US20150259300A1 (en) 2012-10-18 2015-09-17 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
ES2622583T3 (es) 2012-11-15 2017-07-06 Bayer Pharma Aktiengesellschaft 4-(Orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina
US9650340B2 (en) 2012-11-15 2017-05-16 Bayer Pharma Aktiengesellschaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
US9770445B2 (en) 2013-07-04 2017-09-26 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors
CA2942119A1 (en) 2014-03-13 2015-09-17 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

Also Published As

Publication number Publication date
CN105102444A (zh) 2015-11-25
KR102242871B1 (ko) 2021-04-20
SV2015004979A (es) 2017-01-30
IL238322A (en) 2017-08-31
AU2013346939B2 (en) 2017-06-08
JP6263193B2 (ja) 2018-01-17
MX2015006169A (es) 2015-08-10
AP3872A (en) 2016-10-31
AU2013346939A1 (en) 2015-05-14
PE20151071A1 (es) 2015-08-19
HUE032868T2 (en) 2017-11-28
SG11201503079PA (en) 2015-06-29
DK2928878T3 (en) 2016-12-19
HK1213255A1 (zh) 2016-06-30
KR20150084968A (ko) 2015-07-22
US20170202815A1 (en) 2017-07-20
CA2891358A1 (en) 2014-05-22
TW201420569A (zh) 2014-06-01
CY1118441T1 (el) 2017-06-28
CL2015001304A1 (es) 2015-07-17
UY35141A (es) 2014-06-30
TWI613193B (zh) 2018-02-01
LT2928878T (lt) 2016-11-25
US20150291528A1 (en) 2015-10-15
RS55580B1 (sr) 2017-06-30
ME02880B (me) 2018-04-20
BR112015010707A2 (pt) 2017-07-11
PH12015501003A1 (en) 2015-07-27
NZ707084A (en) 2019-09-27
MY170609A (en) 2019-08-20
PL2928878T3 (pl) 2017-04-28
AR093505A1 (es) 2015-06-10
AP2015008432A0 (en) 2015-05-31
SI2928878T1 (sl) 2016-12-30
BR112015010707B1 (pt) 2022-05-17
IL238322A0 (en) 2015-06-30
JP2015537015A (ja) 2015-12-24
DOP2015000118A (es) 2015-06-15
EA027226B1 (ru) 2017-07-31
TN2015000185A1 (en) 2016-10-03
UA115254C2 (uk) 2017-10-10
EA201590890A1 (ru) 2015-11-30
CR20150256A (es) 2015-07-01
ECSP15019323A (es) 2016-01-29
US9877954B2 (en) 2018-01-30
EP2928878A1 (en) 2015-10-14
PH12015501003B1 (en) 2017-10-20
HRP20161547T1 (hr) 2016-12-30
CA2891358C (en) 2021-05-18
JO3332B1 (ar) 2019-03-13
CN105102444B (zh) 2017-08-01
CU20150052A7 (es) 2015-09-29
WO2014076091A1 (en) 2014-05-22
EP2928878B1 (en) 2016-11-02
MX374333B (es) 2025-03-06
ES2612978T3 (es) 2017-05-19
MA38090A1 (fr) 2018-02-28
US9650340B2 (en) 2017-05-16
BR112015010707A8 (pt) 2019-10-01
MA38090B1 (fr) 2018-09-28

Similar Documents

Publication Publication Date Title
AP3872A (en) 5-Fluoro-n-(pyridin-2-yl) pyridin-2-amine derivatives containing a sulfoximine group
ZA201405486B (en) Pyridone derivatives
AP3884A (en) 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
PL2822876T3 (pl) Kapsułka do zaparzania produktów
ZA201503969B (en) Novel pyridine derivatives
IL238370A0 (en) n-(pyridin-2-yl)pyrimidine-4-amine derivatives containing a sulfoximine group
ZA201502685B (en) Capsules
ZA201305227B (en) Pharmaceutical composition comprising pyridone derivatives
IL237128A0 (en) New pyridine derivatives
SG11201504418TA (en) Pyridone compound
GB201207801D0 (en) A frame for artwork
SG11201404082QA (en) A conveyor
GB201203435D0 (en) A baby burping aid
GB201214063D0 (en) Packaging fourteen
AP2012000567S (en) Packaging anti-mosquitos wristband
GB201205609D0 (en) Flavoured device for a baby
GB201220749D0 (en) Capsules
GB201223122D0 (en) Leaflet
GB201214463D0 (en) A capsule
AU347374S (en) A shirt
PH32012000272S1 (en) Decorative elements for packaging